AI Article Synopsis

  • - The study investigates how plasma biomarkers related to metabolism and inflammation (adiponectin, leptin, IL-8, and HGF) are linked to insulin insensitivity in children, particularly focusing on 8-10 and 14-16 year-old Danish participants.
  • - Results show that lower levels of adiponectin at baseline are tied to higher insulin insensitivity six years later among overweight children, while higher leptin levels correlate with current insulin insensitivity in younger children but not over time.
  • - Ultimately, the research highlights a significant association between low adiponectin and increased insulin insensitivity during adolescence, especially in overweight kids, suggesting early metabolic health monitoring may be beneficial.

Article Abstract

Background: Biomarkers of metabolism and inflammation may predict children with increased diabetes risk.

Objective: To study plasma adiponectin, leptin, IL-8, and hepatocyte growth factor (HGF) in childhood and their independent associations with insulin insensitivity, cross-sectional and in 6-yr prospective.

Subjects: Danish 8- to 10-yr-olds and 14- to 16-yr-olds from the European Youth Heart Studies I and II.

Methods: Cross-sectional (n = 386) and prospective (n = 246) linear regressions of baseline concentrations of plasma biomarkers and insulin insensitivity at baseline and 6 yr later. Adjustments were made at four progressive steps for sex, sexual maturity, body mass index (BMI), other biomarkers, physical activity, and school location as well as baseline insulin insensitivity in prospective analyses. Insulin insensitivity was measured using homeostasis model assessment standardized to the sample mean [homoestasis model assessment (HOMA) Z-scores]. Plasma biomarkers were quantified using solid-phase protein immunoassays. Overweight was defined as the highest BMI tertile.

Results: Among overweight but not lean children at baseline, one SD difference in baseline plasma adiponectin was associated with -0.41 SD difference in HOMA Z-scores 6 yr later (p = 0.006). At baseline, one SD difference in plasma leptin was associated with 0.36 SD difference in HOMA Z-scores (p =< 0.0001) among 8- to 10-yr-olds, but a prospective association was not found.

Conclusions: We found a direct relationship between childhood hypo-adiponectinaemia and insulin insensitivity in adolescence. This association was stronger for overweight than for normal weight children. Hyper-leptinaemia was associated with concurrent insulin insensitivity at baseline but not 6 yr later.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-5448.2009.00556.xDOI Listing

Publication Analysis

Top Keywords

insulin insensitivity
28
childhood hypo-adiponectinaemia
8
hyper-leptinaemia associated
8
plasma adiponectin
8
plasma biomarkers
8
insensitivity baseline
8
model assessment
8
baseline difference
8
difference homa
8
homa z-scores
8

Similar Publications

Artificial sweeteners and Type 2 Diabetes Mellitus: A review of current developments and future research directions.

J Diabetes Complications

January 2025

Department of Medical Biochemistry, Faculty of Medicine, Near East University, Nicosia, 99138 TRNC, Mersin 10, Turkey. Electronic address:

While artificial sweeteners are Generally Regarded as Safe (GRAS), the scientific community remains divided on their safety status. The previous assumption that artificial sweeteners are inert within the body is no longer valid. Artificial sweeteners, known for their high intense sweetness and low or zero calories, are extensively used today in food and beverage products as sugar substitutes and are sometimes recommended for weight management and Type 2 Diabetes Mellitus (T2DM) patients.

View Article and Find Full Text PDF

Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity.

Front Endocrinol (Lausanne)

January 2025

Section on Growth and Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Health, Bethesda, MD, United States.

Recombinant human IGF-1 is used to treat severe primary IGF-1 deficiency, but this treatment requires twice-daily injection, often does not fully correct the growth deficit, and has important off-target effects. We therefore sought to target IGF-1 to growth plate cartilage by generating fusion proteins combining IGF-1 with single-chain human antibody fragments that target matrilin-3, a cartilage matrix protein. We previously showed that this cartilage-targeting IGF-1 fusion protein (CV1574-1) promoted growth plate function in a GH-deficient (lit) mouse model.

View Article and Find Full Text PDF

Iron overload increases fasting blood glucose level in mice, leading to insulin insensitivity. However, no such relationship has been shown in the population. The relationship between whole blood iron levels and fasting blood glucose levels remained unclear.

View Article and Find Full Text PDF

A Research Roadmap to Address the Heterogeneity of Diabetes and Advance Precision Medicine.

J Clin Endocrinol Metab

December 2024

Division of Diabetes, Endocrinology & Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

The current classification of diabetes had its genesis over 85 years ago, when individuals with diabetes were first subclassified into insulin sensitive and insulin insensitive states based on the response to an oral glucose tolerance test. About 35 years later, the contemporary classifications of type 1 and type 2 diabetes were coined. Today's evidence, however, suggests that multiple etiologic and pathogenic processes lead to both type 1 and type 2 diabetes, reflecting significant heterogeneity in factors associated with initiation, progression, and clinical presentation of each disorder of glucose homeostasis.

View Article and Find Full Text PDF

Introduction: Laron syndrome (LS) is a rare autosomal recessive disorder caused by mutations in the growth hormone (GH) receptor gene, resulting in GH resistance and reduced levels of insulin-like growth factor 1 (IGF-1). Patients with LS exhibit severe growth retardation, low IGF-1 levels, elevated basal GH, and poor response to GH stimulation. Recombinant IGF-1 is the only approved treatment and has been shown to improve linear growth.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!